HIGHBuilt-inProduct / Revenue mix
57.9%
MedSurg segment
“10-K Item 1: 'MedSurg (57.9% of 2025 total sales)'”
SOLV · Concentration risk · 10-K extracted
Solventum (SOLV) concentration risks
Updated
The most significant concentration Solventum discloses is MedSurg segment at 57.9%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Solventum’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partyCounterparty
3M dependency
“10-K Item 1A: 'Solventum is relying on 3M to satisfy its obligations under the 3M Agreements not only for a successful transition but also for the success of its long-term operations.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile has two exposures: a high-share product segment concentration and a moderate-share counterparty dependency tied to the company's origins as a corporate carve-out. The MedSurg segment accounted for 57.9% of 2025 total sales, a high-share structural exposure reflecting the deliberate positioning of the business around medical device consumables, wound care, and infection prevention products. This concentration is structural in character — the segment represents the core of the company's product strategy following the separation from its former parent — and it means that demand dynamics, pricing power, and competitive pressures in medical-surgical consumables have a disproportionate bearing on consolidated results. The counterparty dependency is distinct and structural in a different sense: the company relies on 3M to satisfy its obligations under the 3M Agreements not only for a successful transition but also for the success of its long-term operations, a moderate-share dependency reflecting the continuing services, supply agreements, and transitional arrangements that flow from the separation. Because the company was carved out of 3M rather than built independently, critical operational infrastructure — including supply chains, services, and potentially certain intellectual property arrangements — still depends on the former parent's continued performance. This dependency is expected to diminish over time as the company establishes independent operational capabilities, but in the near term it represents a counterparty risk that is not present in companies with fully autonomous operational histories. Together the MedSurg segment concentration and the 3M transitional dependency are the two dimensions to monitor, with the 3M reliance being the more time-sensitive variable.
For the engine’s reasoning on SOLV’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| BAX | Baxter International Inc. | 1 | 2 | 0 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| BDX | Becton, Dickinson and Company | 1 | 1 | 0 | 2 |
| SOLV● | Solventum Corporation | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.